

14.05.2025

Category: Company

## Rodenstock achieves revenue and earnings growth in the financial year 2024

Growth of the B.I.G. VISION® product portfolio and high demand for MyCon lenses contribute to robust business results

- Moderate revenue increase on a comparable basis of +1.2% to EUR 512.4 million despite ongoing macroeconomic challenges
- Solid increase in adjusted EBITDA of EUR +6.3 million to EUR 128.6 million on a comparable basis
- Strong key account business (excl. GrandVision) grows by +11% compared to the previous year in an uncertain market environment

- Increased efficiency and high demand for innovative products ensure a positive growth outlook for 2025

The Rodenstock Group ("Rodenstock"), a global innovation leader in Vision Care and high-quality manufacturer of biometric lenses, today announced its results for the financial year 2024. Fueled by sustained growth in demand for the B.I.G. VISION® product portfolio for biometric lenses and MyCon<sup>TM</sup> lenses for children, Rodenstock increased consolidated net sales to 512.4 million euros (2023: 506.1 million euros).

The 2024 financial year was characterized by ongoing geopolitical and economic challenges. Despite the uncertain market environment, Rodenstock achieved an adjusted EBITDA of EUR 128.6 million in 2024, an increase of 5.1% compared to the previous year.

The consistent pursuit of the B.I.G. VISION® strategy has contributed significantly to the solid financial results. It has also strengthened the company's position as a leading Med-Tech company and drove the paradigm shift in individual lenses. Since the market launch of MyCon<sup>TM</sup> lenses in 2023, sales have increased by 62% worldwide in the last year. The innovative lenses for children are designed to correct short-sightedness, ensure sharp vision and counteract the progression of myopia. Additionally, the successful launch of the DNEye® Scanner 3 emphasizes the company's advanced technology and exceptional customer benefits.

The significant double-digit growth of Indo Optical and a notable increase in sales of the B.I.G. VISION® product portfolio for biometric lenses consolidated Rodenstock's leading position in the ophthalmic lens sector.

Marcus Desimoni, CEO of the Rodenstock Group, says: "I would like to thank the entire team for another successful year, especially regarding great benefits for customers that result in very satisfied customers. With the strong performance of our B.I.G. VISION® portfolio, MyCon<sup>TM</sup> lenses and the strategic launch of the DNEye® Scanner 3, we have reached key milestones in our strategy. These achievements provide a strong foundation for further growth."

About Rodenstock:

The Rodenstock Group is one of the world's leading manufacturers of high-quality ophthalmic lenses. With the philosophy "B.I.G. VISION® FOR ALL", the lens manufacturer stands for a paradigm shift in individual progressive lenses. Founded in 1877 and based in Munich, Germany, the company employs around 5,000 people worldwide and is represented by sales offices and distribution partners in more than 85 countries. Rodenstock works with 6 central production sites to ensure global availability. For further information please visit [www.rodenstock.com/press](http://www.rodenstock.com/press).

### Pressekontakt:

Rodenstock GmbH

Ralf Ellermann

Head of Global Marketing, Vice President

+49 172 8981 530

+49 172 8981 530

Ralf.Ellermann@rodenstock.com